Allowing coverage of hemp-derived cannabinoid products under Medicare Advantage as a special supplemental benefit for the chronically ill; codifying substance access beneficiary engagement incentive

(a) Medicare Advantage special supplemental benefit for the chronically ill Section 1852(a)(3)(D)(ii) of the Social Security Act (42 U.S.C. 1395w–22(a)(3)(D)(ii)) is amended by adding at the end the following new subclause: (III) Inclusion of hemp-derived cannabinoid products Beginning with respect to the first plan year beginning after the date of enactment of this subclause, an MA plan may, in accordance with such criteria as the Secretary may specify, include as a supplemental benefit under this subparagraph coverage of a hemp-derived cannabinoid product (as defined in section 201(tt) of the Federal Food, Drug, and Cosmetic Act).. (b) Substance access beneficiary engagement incentive under CMI models Section 1115A of the Social Security Act (42 U.S.C. 1315a) is amended by adding at the end the following new subsection: (h) Substance access beneficiary engagement incentive (1) In general Beginning on the date that is 1 year after the date of enactment of this subsection, a provider of services or supplier participating in a specified model may, in accordance with such criteria as the Secretary shall specify, offer an applicable individual receiving items or services from such provider or supplier a beneficiary engagement incentive consisting of— (A) consultation regarding the possible use of hemp-derived cannabinoid products (as defined in section 201(tt) of the Federal Food, Drug, and Cosmetic Act); and (B) subject to such limits as the Secretary shall specify, the provision of such hemp-derived cannabinoid products. (2) Specified model For purposes of paragraph (1), a specified model is a model tested under this section for which the Secretary determines that the beneficiary engagement incentive described in such paragraph is appropriate..